Theralase Technologies Inc.: Theralase Launches Fifth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
Theralase or the
TSXV:TLT)(
OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (
PDC ) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that University of Wisconsin Health-Madison (
UWH ) has received site Institutional Review Board (
IRB ) approval to commence a pivotal Phase II Non-Muscle Invasive Bladder Cancer (
NMIBC ) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(
Study II ).
Theralase Launches Fifth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.